Optical Scattering Artifacts Observed in the Development of Multiplexed Surface Enhanced Raman Spectroscopy Nanotag Immunoassays

Noble, James; Attree, Simon; Horgan, Adrian; Knight, Alex E.; Kumarswami, Neelam; Porter, Robert A.; Worsley, Graham J.

doi:10.1021/ac301566k

Cited by 22 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To leverage the benefits of SERS-based detection, POC formats are needed. Toward this end, efforts include the development of SERS-LFA [22] and a one-step homogeneous assay [16]. Most recently, our group has developed a rapid SERS immunoassay in which antibody-antigen binding is accelerated via active transport through an antibody-modified gold filter [17].…”

Section: Introductionmentioning

confidence: 99%

SERS immunoassay based on the capture and concentration of antigen-assembled gold nanoparticles

Lopez

Lovato

et al. 2016

Talanta

View full text Add to dashboard Cite

A simple, rapid, and sensitive immunoassay has been developed based on antigen-mediated aggregation of gold nanoparticles (AuNP) and surface-enhanced Raman spectroscopy (SERS). Central to this platform is the extrinsic Raman label (ERL), which consists of a gold nanoparticle modified with a mixed monolayer of a Raman active molecule and an antibody. ERLs are mixed with sample, and antigen induces the aggregation of the ERLs. A membrane filter is then used to isolate and concentrate the ERL aggregates for SERS analysis. Preliminary work to establish proof-of-principle of the platform technology utilized mouse IgG as a model antigen. The effects of membrane pore diameter and AuNP size on the analytical performance of the assay were systematically investigated, and it was determined that a pore diameter of 200 nm and AuNP diameter of 80 nm provide maximum sensitivity while minimizing signal from blank samples. Optimization of the assay provided a detection limit of 1.9 ng/mL, 20-fold better than the detection limit achieved by an ELISA employing the same antibody-antigen system. Furthermore, this assay required only 60 min compared to 24h for the ELISA. To validate this assay, mouse serum was directly analyzed to accurately quantify IgG. Collectively, these results demonstrate the potential advantages of this technology over current diagnostic tests for protein biomarkers with respect to time, simplicity, and detection limits. Thus, this approach provides a framework for prospective development of new and more powerful tools that can be designed for point-of-care diagnostic or point-of-need detection.

show abstract

Section: Introductionmentioning

confidence: 99%

SERS immunoassay based on the capture and concentration of antigen-assembled gold nanoparticles

Lopez

Lovato

et al. 2016

Talanta

View full text Add to dashboard Cite

show abstract

“…This immunoassay also quantified myoglobin, another important cardiac biomarker, with an LOD of 3.2 pg mL −1 [ 82 ]. This assay shows an increased sensitivity to a previous SERS-based LFIA that used thiol-coated Au@glass core-shell NPs, where the LODs for cTnI and CRP were established in the μg mL −1 range [ 83 ].…”

Section: Cardiovascular Diseasementioning

confidence: 99%

In Vitro and In Vivo SERS Biosensing for Disease Diagnosis

et al. 2018

View full text Add to dashboard Cite

For many disease states, positive outcomes are directly linked to early diagnosis, where therapeutic intervention would be most effective. Recently, trends in disease diagnosis have focused on the development of label-free sensing techniques that are sensitive to low analyte concentrations found in the physiological environment. Surface-enhanced Raman spectroscopy (SERS) is a powerful vibrational spectroscopy that allows for label-free, highly sensitive, and selective detection of analytes through the amplification of localized electric fields on the surface of a plasmonic material when excited with monochromatic light. This results in enhancement of the Raman scattering signal, which allows for the detection of low concentration analytes, giving rise to the use of SERS as a diagnostic tool for disease. Here, we present a review of recent developments in the field of in vivo and in vitro SERS biosensing for a range of disease states including neurological disease, diabetes, cardiovascular disease, cancer, and viral disease.

show abstract

“…A SERS-based TN immunoassay has also been integrated into the lateral flow immunoassay. For example, one research group has created a single-line multiplexed assay for a TN, MB, and C-reactive protein (CRP), with a range from pg/mL to µg/mL, by functionalizing distinguishable Raman nanoprobes (highlighted at 923, 1160, and 1335 cm -1 ) with appropriate antibodies for each analyte [100]. On this platform, the TN was successfully measured in a 15 μL sample in the presence or absence of CRP.…”

Section: Sers-based Tn Detection System With Nanostructurementioning

confidence: 99%

Development of the Troponin Detection System Based on the Nanostructure

et al. 2019

View full text Add to dashboard Cite

During the last 30 years, the World Health Organization (WHO) reported a gradual increase in the number of patients with cardiovascular disease (CVD), not only in developed but also in developing countries. In particular, acute myocardial infarction (AMI) is one of the severe CVDs because of the high death rate, damage to the body, and various complications. During these harmful effects, rapid diagnosis of AMI is key for saving patients with CVD in an emergency. The prompt diagnosis and proper treatment of patients with AMI are important to increase the survival rate of these patients. To treat patients with AMI quickly, detection of a CVD biomarker at an ultra-low concentration is essential. Cardiac troponins (cTNs), cardiac myoglobin (cMB), and creatine kinase MB are typical biomarkers for AMI detection. An increase in the levels of those biomarkers in blood implies damage to cardiomyocytes and thus is related to AMI progression. In particular, cTNs are regarded as a gold standard biomarker for AMI diagnosis. The conventional TN detection system for detection of AMI requires long measurement time and is labor-intensive and tedious. Therefore, the demand for sensitive and selective TN detection techniques is increasing at present. To meet this demand, several approaches and methods have been applied to develop a TN detection system based on a nanostructure. In the present review, the authors reviewed recent advances in TN biosensors with a focus on four detection systems: (1) An electrochemical (EC) TN nanobiosensor, (2) field effect transistor (FET)-based TN nanobiosensor, (3) surface plasmon resonance (SPR)-based TN nanobiosensor and (4) surface enhanced Raman spectroscopy (SERS)-based TN nanobiosensor.

show abstract

Optical Scattering Artifacts Observed in the Development of Multiplexed Surface Enhanced Raman Spectroscopy Nanotag Immunoassays

Cited by 22 publications

References 24 publications

SERS immunoassay based on the capture and concentration of antigen-assembled gold nanoparticles

SERS immunoassay based on the capture and concentration of antigen-assembled gold nanoparticles

In Vitro and In Vivo SERS Biosensing for Disease Diagnosis

Development of the Troponin Detection System Based on the Nanostructure

Contact Info

Product

Resources

About